Matyas Lakatos

I help boards and leadership teams see the commercial path early, while there is still time to shape science, data and partnerships. That judgement comes from 25 years at Novo Nordisk, Takeda and Amgen, including global launch strategy for Ozempic and a GLP-1 franchise now past $30B. As Project Vice President for oral semaglutide, I held a role much like a board%27s: accountable for a cross-functional budget, challenging and guiding functions I didn%27t run.

I bring the same balance of challenge and support to my advisory work with Evoleen, OmicsAI, Loyal VC and THENA Capital, on go-to-market, ecosystem partnerships and global expansion.

I fit best with post-Series B biotechs, scaleups and mid-sized pharma or health-tech companies in cardiometabolic, IBD/GI or rare disease, ready to grow beyond their current position. Physician and MBA, based in Zurich.